Novo Nordisk A/S

LSE:0QIU Stock Report

Market Cap: kr.4.0t

Novo Nordisk Valuation

Is 0QIU undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0QIU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0QIU (DKK902.6) is trading below our estimate of fair value (DKK938.64)

Significantly Below Fair Value: 0QIU is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0QIU?

Other financial metrics that can be useful for relative valuation.

0QIU key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue17.3x
Enterprise Value/EBITDA36.6x
PEG Ratio3.3x

Price to Earnings Ratio vs Peers

How does 0QIU's PE Ratio compare to its peers?

The above table shows the PE ratio for 0QIU vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average27.6x
AZN AstraZeneca
36.9x16.6%UK£187.0b
GSK GSK
13.9x9.3%UK£68.4b
HIK Hikma Pharmaceuticals
28.1x18.0%UK£4.3b
HCM HUTCHMED (China)
31.5x17.5%UK£2.5b
0QIU Novo Nordisk
48.1x14.7%kr.4.0t

Price-To-Earnings vs Peers: 0QIU is expensive based on its Price-To-Earnings Ratio (48.1x) compared to the peer average (27.6x).

Price to Earnings Ratio vs Industry

How does 0QIU's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a14.8%
 n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a14.8%
 n/an/an/a
No more companies

Price-To-Earnings vs Industry: 0QIU is expensive based on its Price-To-Earnings Ratio (48.1x) compared to the European Pharmaceuticals industry average (25.2x).

Price to Earnings Ratio vs Fair Ratio

What is 0QIU's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0QIU PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio48.1x
Fair PE Ratio58.7x

Price-To-Earnings vs Fair Ratio: 0QIU is good value based on its Price-To-Earnings Ratio (48.1x) compared to the estimated Fair Price-To-Earnings Ratio (58.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0QIU forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentkr.902.60
kr.904.20
+0.2%
19.4%kr.1,120.00kr.530.00n/a25
Apr ’25kr.881.30
kr.894.24
+1.5%
19.6%kr.1,120.00kr.530.00n/a25
Mar ’25kr.850.99
kr.785.08
-7.7%
24.1%kr.975.00kr.140.00n/a24
Feb ’25kr.783.72
kr.737.84
-5.9%
24.7%kr.950.00kr.140.00n/a24
Jan ’25kr.698.10
kr.689.43
-1.2%
27.4%kr.875.00kr.120.00n/a23
Dec ’24kr.698.70
kr.680.04
-2.7%
27.2%kr.875.00kr.120.00n/a23
Nov ’24kr.687.70
kr.683.48
-0.6%
21.1%kr.825.00kr.360.00n/a22
Oct ’24kr.651.28
kr.648.75
-0.4%
19.7%kr.810.00kr.360.00n/a22
Sep ’24kr.644.80
kr.618.30
-4.1%
18.1%kr.775.00kr.360.00n/a22
Aug ’24kr.543.60
kr.583.13
+7.3%
15.8%kr.725.00kr.360.00n/a23
Jul ’24kr.550.96
kr.579.06
+5.1%
16.2%kr.725.00kr.360.00n/a22
Jun ’24kr.549.30
kr.574.51
+4.6%
16.8%kr.725.00kr.360.00n/a22
May ’24kr.564.86
kr.559.05
-1.0%
19.5%kr.725.00kr.340.00kr.902.6022
Apr ’24kr.542.90
kr.510.61
-5.9%
18.6%kr.620.00kr.340.00kr.881.3022
Mar ’24kr.499.22
kr.489.63
-1.9%
17.0%kr.610.00kr.340.00kr.850.9923
Feb ’24kr.471.20
kr.475.37
+0.9%
18.3%kr.600.00kr.270.00kr.783.7223
Jan ’24kr.469.28
kr.449.57
-4.2%
15.4%kr.542.50kr.270.00kr.698.1023
Dec ’23kr.446.79
kr.436.25
-2.4%
15.9%kr.542.50kr.270.00kr.698.7024
Nov ’23kr.406.26
kr.425.66
+4.8%
15.6%kr.535.00kr.270.00kr.687.7025
Oct ’23kr.380.70
kr.418.04
+9.8%
16.5%kr.512.50kr.270.00kr.651.2826
Sep ’23kr.396.41
kr.414.19
+4.5%
16.3%kr.512.50kr.270.00kr.644.8026
Aug ’23kr.424.47
kr.413.73
-2.5%
16.9%kr.512.50kr.270.00kr.543.6026
Jul ’23kr.392.24
kr.406.50
+3.6%
16.3%kr.502.50kr.270.00kr.550.9626
Jun ’23kr.381.10
kr.397.94
+4.4%
17.5%kr.502.50kr.270.00kr.549.3026
May ’23kr.406.33
kr.382.96
-5.8%
17.3%kr.480.00kr.270.00kr.564.8624

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.